We are very pleased to announce that the US FDA has granted Breakthrough Device Designation for our #RaDaR #MRD #LiquidBiopsy assay. Read more on our website: #MRD #Cancer

ICYMI #TeamInivata and collaborators presented ‘Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer (NABUCCO)’ at #ESMO22. View here: @myESMO #MRD #data

Join millions who have switched to Grok.

Come and meet #TeamInivata at this year’s 12th Annual World Clinical Biomarkers & #CDx Summit, taking place from 26-29 September. Find out more here: #drugdevelopment #diagnostics #oncology.

ICYMI #TeamInivata and collaborators presented a poster on ‘Liquid biopsy for detection of molecular residual disease and recurrence in head and neck squamous cell carcinoma’ at #ESMO22. View here: @myESMO #data #presentation

In this #blog, Beverly talks about the strength of the team, and how Inivata works with our #pharma partners to support the development of life-changing cancer #therapeutics from early-stage drug pipelines through to therapeutic delivery at the #patient level. #OneNeo.

Follow our mini-Q&A series to get to know the #BusinessDevelopment team at Inivata and hear what inspires them to come to work every day and be part of #TeamInivata. This time, VP BD, Beverly Monahan, talks about her experience:.#OneNeo

We will be attending the 12th Annual World Clinical Biomarkers & CDx Summit, taking place from 26-29 September in Boston. Our colleagues at @NeoGenomics will also be delivering a #presentation entitled ‘From Bench to Bedside: A CDx Odyssey’. #event

In this #blog, Huw discusses the opportunities he has at Inivata to explore #partnerships within the #oncology space and looks to the future, sharing his view on where the #liquidbiopsy market is heading over the next 5 years. #InivataInsight #OneNeo.

In a new, multipart series, we’ll be hearing from our #BusinessDevelopment team on what excites them about working as part of #TeamInivata and finding out more about their roles in the company. Firstly, hear from Huw Ricketts, SVP BD: #OneNeo

#TeamInivata and its collaborators’ poster titled ‘Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer (NABUCCO) won best poster in the session today at #ESMO22. @myESMO

Later today, #TeamInivata and collaborators will be presenting a poster, titled ‘Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer (NABUCCO)’ at 3-4pm CEST at #ESMO22. @myESMO

Don’t miss our RaDaR #data being shared on Sunday at #ESMO22. #TeamInivata and collaborators will be presenting a poster titled ‘Liquid biopsy for detection of molecular residual disease and recurrence in head and neck squamous cell carcinoma’ at 2-3pm CEST. @myESMO

The @myESMO congress kicks off tomorrow. For meetings, please contact Vishal Sikri, David Eberhard, Mike Nahorski, Huw Ricketts or Chris Pipinikas or get in touch at: #ESMO22

Our CMO, David Eberhard, recently spoke with @GENBio about the challenges of detecting #MRD and how #liquidbiopsies can address these. Click below to read more about how we are working to transform care for cancer patients. .#drugdevelopment #oncology.

#TeamInivata, alongside its collaborators, will present new #data on our #RaDaR™ assay for the detection of #MRD and recurrence at the @myESMO Congress, taking place between 9-13 September 2022. Read more here: #ESMO22

This September, Inivata is once again supporting #GynecologicCancerAwarenessMonth. Join us in highlighting the importance of bringing awareness to all gynecologic cancers. Get involved here:

The @myESMO Annual Meeting takes place next month. Members of #TeamInivata will be on the ground in Paris. For meetings, please contact Vishal Sikri, David Eberhard, Mike Nahorski, Huw Ricketts and Chris Pipinikas. #ESMO22

Great to see in @ICR_London, alongside many other key stakeholders, supporting the use of biomarker testing to improve cancer patient diagnosis & care. Read more in this article from @thetimes:..#diagnostics #oncology #liquidbiopsy.

At Inivata, our purpose is to help guide more informed #treatments for cancer patients. To hear the story of the first #patient tested with our InVisionFirst-Lung #liquidbiopsy test for #NSCLC, please see below.

ICYMI, we shared a poster presentation on “Plasma first: Accelerating lung #cancer diagnosis through liquid biopsy” at the 2022 ASCO® Annual Meeting. See here: #ASCO22

Today is #WorldLungCancerDay, a day focused on raising awareness of the challenges of #lungcancer - which accounts for nearly 1/5 cancer deaths globally. At Inivata, we show our support for all those impacted and remain committed to helping transform care for cancer #patients.